Key result
Pimobendan was associated with a significantly longer median survival time compared to standard treatment in cats with non-taurine responsive dilated cardiomyopathy (49 vs 12 days; P=0.048).
Why the study?
Does pimobendan improve median survival time in cats with non-taurine responsive dilated cardiomyopathy?
Cohort (n=32)
Does pimobendan improve median survival time in cats with non-taurine responsive dilated cardiomyopathy?
Absolute Event Rate: 49% vs 12%
p-value: p=0.048
Pimobendan significantly prolongs survival in cats with non-taurine responsive dilated cardiomyopathy compared to standard therapy alone.
Authors
No takes yet. Share an insight, caveat, or question.
May support pimobendan in feline non-taurine responsive DCM; hypothesis-generating and requires prospective randomized confirmation.
Hambrook et al. (2012) conducted a cohort in non-taurine responsive dilated cardiomyopathy (DCM) (n=32). Pimobendan vs. Non-pimobendan (standard treatment) was evaluated on median survival time (MST) (p=0.048). Pimobendan was associated with a significantly longer median survival time compared to standard treatment in cats with non-taurine responsive dilated cardiomyopathy (49 vs 12 days; P=0.048).